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A B S T R A C T
A systematic review with meta-analyses was performed to: 1) quantify the association between ADHD and risk of
unintentional physical injuries in children/adolescents (“risk analysis”); 2) assess the effect of ADHD medica-
tions on this risk (“medication analysis”). We searched 114 databases through June 2017. For the risk analysis,
studies reporting sex-controlled odds ratios (ORs) or hazard ratios (HRs) estimating the association between
ADHD and injuries were combined. Pooled ORs (28 studies, 4,055,620 individuals without and 350,938 with
ADHD) and HRs (4 studies, 901,891 individuals without and 20,363 with ADHD) were 1.53 (95%
CI = 1.40,1.67) and 1.39 (95% CI = 1.06,1.83), respectively. For the medication analysis, we meta-analysed
studies that avoided the confounding-by-indication bias [four studies with a self-controlled methodology and
another comparing risk over time and groups (a “difference in differences” methodology)]. The pooled effect size
was 0.879 (95% CI = 0.838,0.922) (13,254 individuals with ADHD). ADHD is significantly associated with an
increased risk of unintentional injuries and ADHD medications have a protective effect, at least in the short term,
as indicated by self-controlled studies.
1. Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD), characterized by
a persistent, age inappropriate, and impairing pattern of inattention
and/or hyperactivity-impulsivity (American Psychiatric Association,
2013), is the most commonly diagnosed neurodevelopmental disorder.
Its worldwide prevalence is estimated to be about 5% in school-age
children (Polanczyk et al., 2014). Hyperkinetic Disorder (HKD), as
defined in the International Classification of Diseases, 10th Edition
(ICD-10) (World Health Organization, 2016), is a narrower diagnostic
category, requiring both symptoms of inattention and hyperactivity/
impulsivity, similarly to the combined presentation of ADHD as per the
Diagnostic and Statistical Manual of Mental Disorders fifth edition
(DSM-5). ADHD is more frequent in males than in females, with male-
to-female ratios of 3:1 in population-based samples and even higher
(from 6:1 to 9:1) in clinical samples, probably due to referral bias (Gaub
and Carlson, 1997). ADHD is often comorbid with other disorders, such
as oppositional defiant disorder (ODD), conduct disorder (CD), and
anxiety disorders (Faraone, 2015). Available treatments for ADHD in-
clude pharmacological and non-pharmacological interventions. Due to
its core symptoms and associated conditions, ADHD imposes huge
burdens on affected individuals, families (Beining, 2014; Kvist et al.,
2013) and society (Doshi et al., 2012; Holden et al., 2013; Le et al.,
2014).
A factor that may contribute to the societal costs of ADHD is its
possible association with an increased risk of unintentional physical
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injuries (UPIs), which in turn may be among the causes of increased
mortality in ADHD (Dalsgaard et al., 2015b). Indeed, core ADHD
symptoms (i.e., inattention, hyperactivity and impulsivity), as well as
characteristics related to comorbid disorders (e.g., aggressiveness as-
sociated with ODD/CD) may increase the risk of UPIs. However, despite
a number of studies (e.g., (Bonander et al., 2016; Dalsgaard et al.,
2015a; Lange et al., 2016)) reporting a significantly increased risk of
UPIs in individuals compared to those without ADHD, available find-
ings are quite mixed (e.g. (Dudani et al., 2010; Sciberras et al., 2016)).
Some of the most recent studies have found statistically significant ef-
fect sizes with odds ratios (ORs) below 2. For example, a study fol-
lowing over 700,000 Danish children estimated the OR of suffering an
injury at age 12 in ADHD compared to controls as 1.3 (95% Confidence
Interval, CI = 1.23, 1.37) (Dalsgaard et al., 2015a), whereas a German
study surveying over 350,000 participants found an OR of 1.55 (95%
CI = 1.49, 1.71) (Lange et al., 2016). In contrast, a population-based
survey from Canada including over 1.5 million individuals did not find
a relation between ADHD an injuries when comorbidity was accounted
for (OR = 0.75, 95% CI = 0.53, 1.06) (Dudani et al., 2010), and an-
other recent population-based survey across Europe with over 4,000
participants found similar results (OR = 0.91, 95% CI = 0.56, 1.48)
(Keyes et al., 2014). Moreover, some case-control studies have reported
much higher and statistically significant odds ratios (Ghanizadeh, 2008;
Shilon et al., 2012). Summarizing, the exact extent to which ADHD in
children and adolescents is associated with an increased risk of UPIs,
even after controlling for comorbid conditions, is still unclear.
Perhaps even more importantly, meta-analytic evidence on possible
beneficial or harmful effects of ADHD medications on the risk of UPIs is
lacking. To the best of our knowledge, no randomized controlled trials
have aimed to assess the effects of ADHD medications and the risk of
injuries, possibly due to the relatively low incidence of injuries. Hence,
studies using observational data can offer useful information on the
association, provided appropriate methodologies are applied. Whilst
case-control studies aimed at addressing the effect of ADHD medication
on risk of UPIs are hampered by the “confound by indication” bias
(pharmacological treatment is more common in children with severe
compared to mild forms of ADHD), self-controlled case series (SCCS)
studies or other methodologies that take into account individual dif-
ferences have a suitable design to explore this issue.
Gaining insight into the magnitude of the association between
ADHD and risk of UPIs in children and adolescents, as well as on a
possible beneficial or harmful effect of ADHD medications, is highly
relevant from a clinical and public health standpoint. In particular,
meta-analytic evidence of a significant association between ADHD and
increased risk of injuries and of a protective role of ADHD pharma-
cotherapy could inform the debate regarding the discontinuation of
medication during week-ends or school holidays (Ibrahim and Donyai,
2015). Furthermore, findings of a protective effect of medication would
contribute to the current, controversial scientific debate around the
actual benefits and risks of ADHD medications (Banaschewski et al.,
2016).
Of note, a recent meta-analysis by Amiri et al. (Amiri et al., 2017)
pooled 35 studies published until 2014 and found a pooled odds ratio in
children of 1.96 (95% CI = 1.6, 2.4), indicating that ADHD is sig-
nificantly associated with a risk of injury. However, several methodo-
logical sound studies have been published in the past three years, which
could not be included in this previous meta-analysis, and some other
important (for example, the above mentioned Canadian survey by
(Dudani et al., 2010) were not included. Additionally, the Amiri et al.
study did not control for gender effects, which are a crucial confounder
due to the association of both risk of UPIs and ADHD to male gender
(Gaub and Carlson, 1997; Peden et al., 2008). Finally, and importantly,
the meta-analysis by Amiri et al. was not aimed to assess the impact of
ADHD medications on the risk of UPIs.
The present meta-analysis extends in important ways the meta-
analysis by Amiri et al. including studies in children and adolescents
published until June 2017, controlling for gender and, importantly,
exploring the effects of ADHD medication by pooling self-controlled
studies. We hypothesized that: 1) the prevalence of UPIs would be
higher in children/adolescents with compared to those without ADHD;
2) the risk of UPIs would be significantly lower when children/ado-
lescents with ADHD are treated with ADHD-approved medications for
the disorder compared to when they are not treated pharmacologically.
2. Methods
Methods were developed according to the MOOSE (Stroup et al.,
2000) and PRISMA (Liberati et al., 2009) recommendations. The pro-
tocol was registered in the Prospective Register of Systematic Reviews
(PROSPERO, ID = CRD42017064967) and was published in (Ruiz-
Goikoetxea et al., 2017).
2.1. Data sources and searches
We searched PubMed, Scopus, Web of Science and a large number of
other databases from inception to June 2017, with no date/language
restrictions. We also scanned references of retrieved pertinent papers to
find additional studies. See additional details, including search syntax,
in Methods S1 and S2 (Supplementary material).
2.2. Study selection
2.2.1. Study type
We pooled data from published or unpublished studies that con-
trasted the risk of having suffered an UPI in children and/or adolescents
with ADHD and in typically developing individuals (for the “Risk ana-
lysis”), and in individuals with ADHD while taking and not taking
medication (for the “Medication analysis”). We also included studies
comparing medicated and non- medicated children/adolescents with
ADHD for a qualitative review. We included any type of empirical study
regardless of the design, the temporality (i.e., prospective, retrospective
or cross-sectional) or setting (clinical or epidemiological). Because both
ADHD (Gaub and Carlson, 1997) and the risk of injury (Peden et al.,
2008) are more common in males than in females, to avoid an im-
portant bias, we only included studies that controlled for sex differences
between individuals with and without ADHD, either by sample selec-
tion or statistically.
2.2.2. Population
ADHD: children and/or adolescents (< 18 years) with: 1) a cate-
gorical diagnosis of DSM-5 (American Psychiatric Association, 2013)
(or previous editions) ADHD or with HKD as per the ICD (World Health
Organization, 2016); or 2) use of a symptom threshold on a validated
ADHD rating scale; or 3) a positive answer to questions like: “Did your
doctor ever tell you that you have ADHD?”; 4) a medical record diag-
nosis of ADHD; or 5) being prescribed ADHD medication(s). We ex-
cluded studies including only pre-schoolers (since the methods for the
assessment of ADHD in this population are still matter of discussion,
(e.g.: (Fiks et al., 2016)) as well as those using the diagnosis of “Deficits
in attention, motor control, and perception” (DAMP (Gillberg, 2003)),
or equivalent constructs (Magallon et al., 2015). Comparisons: Parti-
cipants without ADHD (defined as above).
2.2.3. Intervention/exposure
For the meta-analysis of risk, we considered ADHD as exposure. As
for the medication analysis, we considered the impact of the most
commonly used ADHD drugs worldwide, namely methylphenidate,
amphetamine derivatives and atomoxetine.
2.2.4. Outcomes
We considered studies reporting data on unintentional injuries de-
fined according to the S00-T98 codes of the ICD-10 (World Health
M. Ruiz-Goikoetxea et al. Neuroscience and Biobehavioral Reviews 84 (2018) 63–71
64
Organization, 2016), as reported in medical registries, recorded in
medical histories, or self-reported. We did not consider traumatic brain
injury (TBI) or concussion as an outcome as they may introduce bias,
since TBI can increase attentional and impulsivity problems, as well as
the risk of an ADHD diagnosis (Adeyemo et al., 2014). In this regard,
the relationship between TBI and ADHD is likely bidirectional and
complex. Whereas ADHD could increase the risk of future TBIs, brain
injury is likely related to an increase in the risk of ADHD diagnosis. We
assumed that this complex relationship would not be easy to disen-
tangle in the included studies and hence, including studies focusing on
TBI could bias our final estimation of differential risk.
We also excluded studies focusing on intoxications or self-inflicted
injuries (e.g., self-mutilations), which were beyond the scope of this
study.
2.3. Identification and selection of studies
The process included two stages: 1) Two investigators
independently and blindly screened retrieved titles and abstracts of all
non-duplicated papers and excluded those clearly not pertinent. A final
list was agreed with discrepancies resolved by consensus between the
two authors. 2) The full-text versions of the articles passing stage 1 were
assessed for eligibility following the same process. Data from multiple
reports of the same study were linked together. If required, we con-
tacted the corresponding author to inquire on study eligibility.
2.4. Data extraction
Two investigators independently and blindly performed extraction
of data relevant to the present meta-analysis. Study quality and bias,
including confounding, were assessed using the Newcastle-Ottawa Scale
(NOS) (Wells et al., n.d.) (for items included in this scale, see Methods
S3 in supplementary material), as recommended by the Cochrane col-
laboration (Higgins and Green, 2011). Discrepancies were resolved by
consensus. Additional details on outcome selection and data extraction
are reported in Methods S4 (Supplementary Material).
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses Flow Diagram.
Legend: flow diagram of the record identification and study selection. The total amount of studies is not the exact sum of in the number of studies included in the final row of boxes, as
some articles were included in more than one subanalysis. Similarly, articles with linked data were aggregated into single studies (see Results S1 in Supplementary Material).
M. Ruiz-Goikoetxea et al. Neuroscience and Biobehavioral Reviews 84 (2018) 63–71
65
2.5. Data synthesis
ORs/HRs expressing the association between ADHD and UPIs in
children and adolescents were extracted from articles or calculated
from available data. Whenever an article fulfilled all other inclusion
criteria, but did not report enough data to calculate ORs, authors were
contacted.
For the meta-analysis of risk, we calculated a population-average
effect size through the combination of the most general and better
statistically controlled outcome per study. If there were more than one
possible outcome fulfilling these criteria, they were all included in the
analysis. To deal with the non-independence of outcomes, we used
Robust Variance Estimation (RVE) (Hedges et al., 2010). We carried a
similar analysis with Hazard Ratios (HRs) obtained from Cox models.
For the analysis on the effect of medications, we 1) qualitatively
reviewed studies comparing groups of medicated and unmedicated in-
dividuals; 2) statistically pooled effect sizes obtained from studies
taking a within subject approach. First, we combined the incident rate
ratio (IRR) obtained from self-controlled studies. Then, these were
pooled with the results from others studies that were deemed eligible
(i.e., that controlled for individual characteristics) but used different
statistical metrics. Studies on the effect of medications were combined
using a fixed-effect model (Borenstein et al., 2010). We expected the
final model to include only a small number of studies and estimation of
random-effects models with few studies has been shown to be unreli-
able (Guolo and Varin, 2017). However, random-effects models were
carried out in a sensitivity analysis.
We used Q-Cochran’s and the I2 index (Higgins et al., 2003) to
evaluate heterogeneity between studies and the Begg’s adjusted rank
correlation and Egger’s test to formally assess the presence of “small-
sample” bias. To test the robustness of the findings, we conducted
multiple sensitivity analyses (Methods S5). Finally, we performed meta-
regression analyses considering as dependent variables the NOS rating
or age, and comparing effect sizes between sexes. We also compared the
effect sizes of outcomes in which the effect of comorbidity with ODD
and CD had been controlled to those in which it had not been con-
trolled. Analyses were carried out in STATA v13 and R v3.2.2. Forest
plots were created using the DistillerSR Forest Plot Generator from
Evidence Partners. Additional details are reported in Methods S5.
3. Results
Fig. 1 shows the PRISMA flowchart. Studies not included in the
meta-analysis after assessment of the full text are listed, with reasons
for exclusion, in Table S1.We retained 30 studies for the risk analysis
(described in Results S1 and Table S2-S6 in Supplementary Material)
(Bijur et al., 1988; Bonander et al., 2016; Brehaut et al., 2003; Bruce
et al., 2007; Chou et al., 2014; Christoffel et al., 1996; Constant et al.,
2014; Dalsgaard et al., 2015a; Dudani et al., 2010; Fleming et al., 2017;
Ghanizadeh, 2008; Guo et al., 2016; Hire, 2016; Hurtig et al., 2016;
Jensen et al., 1988; Kang et al., 2013; Keyes et al., 2014; Lalloo et al.,
2003; Lam et al., 2006; Lange et al., 2016; Leibson et al., 2001; Maxson
et al., 2009; Odoi et al., 2002; Pastor and Reuben, 2006; Prasad, 2016;
Rowe et al., 2004; Sciberras et al., 2016; Shilon et al., 2012; Silva et al.,
2014; Spinks et al., 2008; Swensen et al., 2004; Tai et al., 2013; Xiang
et al., 2005). As for the medication analysis, we found ten studies that
did not control for individual characteristics. They are qualitatively
summarized in Table S7, with results from individual studies being very
variable. Additionally, we found five studies that controlled for in-
dividual participant characteristics (Dalsgaard et al., 2015a; Man et al.,
2015; Mikolajczyk et al., 2015; Raman et al., 2013; van den Ban et al.,
2014) (Table 1). A report by Dalsgaard is included in the qualitative
analysis (Dalsgaard et al., 2014), whereas another report from the same
authors using the same database is included in the statistical pooling
(Dalsgaard et al., 2015a), reason why only 14 studies are counted in
Fig. 1. Overall, we included 350,938 children or adolescents with
ADHD in the risk meta-analysis based on ORs; 20,363 in the risk meta-
analysis based on HRs; 13,254 in the medication meta-analysis and at
least 10-fold more individuals without ADHD (4,055,620 for OR and
901,891 for HR).
The OR meta-analysis of risk using the most general and controlled
outcomes included 56 outcomes from 28 articles. It indicated a sig-
nificantly higher risk of injuries in ADHD compared to children or
adolescents without ADHD (OR = 1.53, 95% CI = 1.40, 1.67; Fig. S4).
Heterogeneity of studies was significant (X2 = 106.55, df = 27,
p = < 0.001, I2 = 74.7%). Risk of small sample bias was not sig-
nificant (Egger t = 0.81, p = 0.424; Begg Z = 0.57, p = 0.580).
Results were robust to all sensitivity manipulations (Results S2).
Regarding risk of bias, a metaregression including the NOS scores as a
regressor showed no significant effects (Beta Coefficient-B- =−0.018,
95% CI =−0.114, 0.078, p = 0.674). None of the other metaregres-
sion analyses carried out to investigate the effect of variables of clinical
interest such as age (B=−0.001, 95% CI =−0.069, 0.068,
p = 0.984) or sex (B= 0.071, 95% CI =−0.061, 0.204, p = 0.205)
were statistically significant. The comparison of the average effect sizes
in studies controlling for ODD against studies that did not control for
these variables was not statistically significant (B= 0.32,
CI =−0.152, 0.794, p = 0.119).
Similarly to the meta-analysis of ORs, the meta-analysis of HRs
showed a significantly increased risk of injuries in children and ado-
lescents with ADHD (OR = 1.39, 95% CI = 1.06, 1.83, Fig. S5).
Heterogeneity of studies was significant (X2 = 13.36, df = 3,
p = 0.004, I2 = 77.5%). Risk of small sample bias was not significant
(Egger t = 0.08, p = 0.940; Begg Z = 0.68, p = 0.497).
Four of the studies on the effect of medications used a self-con-
trolled methodology (Man et al., 2015; Mikolajczyk et al., 2015; Raman
et al., 2013; van den Ban et al., 2014). Their sample sizes ranged be-
tween 328 and 4934 ADHD children and adolescents who had been
injured and had been taking medication at some point of the exposure
time (total sample: 8679 individuals with ADHD). Three of the samples
were from Europe and the remaining from Taiwan. Methylphenidate
was the most frequent drug among children and adolescents with
ADHD. The fixed-effects combination of the self-controlled studies
showed a significant protective effect of the medication (0.898, 95%
CI = 0.851, 0.948). Of note, heterogeneity of studies was not sig-
nificant (X2 = 4.46, df = 3, p = 0.215, I2=32.8%). Risk of small
sample bias was not significant either (Egger t =−2.30, p = 0.148,
Begg Z =−1.36, p = 0.174). The study by Dalsgaard et al. (Dalsgaard
et al., 2015a) used a different statistical measure comparing the risk
over time and groups (a “difference in differences” methodology) in
which each individual acts as their own control and adjustments for
time trends are carried out with a control group. The authors followed a
cohort of 710,120 Danish children (4557 of which had ADHD), and
found that medication reduced the prevalence of injuries between age
five and 12 by up to 45.5% (95% CI = 18.1%, 69.0%). Additionally, the
authors provided an OR derived from comparing the medicated and
unmedicated groups in an adjusted linear mixed model. The fixed-ef-
fects combination of the self-controlled studies and the OR provided by
this latter study yielded a pooled effect size of 0.879 (95% CI = 0.838,
0.922; Fig. 2). Heterogeneity (X2 = 7.10, df = 4, p = 0.130,
I2=43.8%) and risk of small sample bias (Egger t =−1.90, p = 0.153,
Begg Z =−0.98, p = 0.327) were non-significant. Further statistical
details on all analyses are provided in Results S2 and Figs. S1 to S4
(Supplementary Material). Supplementary analyses also included
random-effects models of the effect of medication which showed very
similar results to those of the main analysis.
4. Discussion
We carried out a systematic review/meta-analysis of published and
unpublished data to 1) quantify the risk of UPIs in children/adolescents
with ADHD and 2) assess the effect of ADHD medication, pooling
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estimates from studies with an adequate design, i.e., self- controlled
case series comparing the rates of injuries in the same individuals when
individuals were medicated compared to when they were not or other
highly controlled methodologies. We found that ADHD was sig-
nificantly associated with an increased risk of injuries in children/
adolescents and that its pharmacological treatment had a protective
effect.
As for the meta-analysis of risk, we pooled studies presenting odds
ratios (ORs) as well as those including hazard ratios (HRs). ORs were
the most commonly reported outcomes: their combination yielded a
significant pooled OR of 1.53 with very small, and hence precise,
confidence intervals (95% CI = 1.40, 1.67). We note that, since it is not
infrequent for children to have more than one injury over time, follow-
up periods could have influenced results. However, it is important to
highlight that the meta-analysis of HR obtained from Cox models, in
which we were able to include outcomes from large databases that are
time-independent, provided similar results (HR = 1.39, 95%
CI = 1.06, 1.83). Moreover, results were similar when we pooled re-
sults from studies with less (OR = 1.50, 95% CI = 1.36, 1.67) or more
than a year of follow-up (OR = 1.54, 95% CI = 1.30, 1.84). It is also
relevant that our results were robust to all sensitivity analyses, in-
dicating that the type of OR (adjusted or unadjusted), the method used
to diagnose ADHD, the definition of injury and the period during which
the study was conducted did not significantly affect the results.
Likewise, our meta-regression analysis showed that the study quality
did not significantly influence the results. Additionally, our meta-re-
gression analyses did not provide evidence for a significant effect of
age, gender or comorbidity. However, these results should be taken
with caution given the number of studies the analyses relied on, and
warrant future studies.
Our study addresses some limitations of a previous meta-analysis on
the risk of injuries in children ADHD by Amiri et al. (Amiri et al., 2017).
These authors obtained both a more variable and higher estimation of
UPIs in children with ADHD (pooled OR = 1.96, 95% CI = 1.6, 2.4).
This may be accounted for by the fact that, compared to our meta-
analysis, they included studies that did not control for gender, which is
an important confounder. Moreover, differently from what we did,
Amiri et al. (Amiri et al., 2017) combined different effect measures
(ORs, HRs and rates) within the same analysis, included studies on pre-
schoolers and also accepted studies that did not use a dichotomous
threshold for clinical scales. All these factors likely contributed to the
variability of their results. Additionally, the fact that we used a wider
search strategy over multiple databases and included a larger time
period led us to include several cohort and other high-quality studies
not present in their study. These studies summed at least 3,700,000
children and adolescents without ADHD and 329,000 with ADHD, and
give further confidence on our estimation compared to the previous
one. Finally, it is also of note that the methods of the present meta-
analysis were pre-registered in an official website for systematic review
protocols (PROSPERO), providing a more transparent analysis.
We also note that we did not include studies focusing on traumatic
brain injuries (TBI), due to the concern that they might introduce
heterogeneity. Indeed, a meta-analysis (Adeyemo et al., 2014) on the
risk of TBI in children with ADHD found even greater ORs (2.1), which
would further prove that the nature of the relation between ADHD and
physical injuries other than TBI is different from that between ADHD
and TBI. It is sensible to hypothesize that ADHD could lead to higher
rates of TBIs and TBIs may lead to higher rates of ADHD diagnoses.
Adeyemo et al. (Adeyemo et al., 2014) found specific support for ADHD
subsequent to TBI, but could not find evidence for asignificant asso-
ciation between ADHD and subsequent TBIs. However, in this previous
meta-analysis, the authors could only locate two studies using a pro-
spective design, a key reason for the exclusion of TBI studies here.
Whereas our work does not directly address the question on the
Table 1
Details of studies included in the medication analysis.
Name Country Risk
Measure
N Medicated N Not-
medicated
Type of medication (%) Age Type of injury
Daalsgard Denmark DID 1457 3100 98.2%MPH NR (5–10) Any
Man China IRR 4934 – 100% MPH 6.9 (6–19) Any
Mikolajczyk Germany IRR 2128 – 92% MPH, 8% Atomoxetine; NR (3–17) Leading to
hospitalization
Raman UK IRR 328 – MPH 76.8% Long-acting MPH 21.7%
Dexamphetamine 1.5%
9.7 (1–18) Any
van den Ban The Netherlands IRR 1289 – MPH and atomoxetine. Percentages are not reported NR (1–18) Leading to
hospitalization
Country: Country where data were collected; Medicated: percentage of medicated ADHD individuals; Age: the age at injury, reported as mean or median age at injury (range). MPH:
Metylphenidate. NR Not reported. IRR: Incident Risk ratio. DID: risk difference in differences.
Fig. 2. Pooled effect size estimating the association between ADHD medication treatment and unintentional injuries in ADHD individuals.
Legend: 4 incident risk ratios and an odds ratio were combined. The area of each square is proportional to the weight that the individual study contributed to the meta-analysis. Weights
are from a fixed-effects model. The diamond indicates the overall weighted mean effect across all studies.
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relationship between ADHD and subsequent TBI, there is no a-priori
reason to believe that this risk is different from the other types of in-
juries included. This specific issue could nevertheless be addressed in
future work. As mentioned in the introduction, all the three core
symptoms of ADHD (i.e., inattention, hyperactivity, and impulsivity), as
well as clinical components often associated with ADHD, such as irrit-
ability and aggression, may increase the risk of injuries. Since studies
included here did not present data according to the ADHD type/pre-
sentation (predominantly inattentive, predominantly impulsive or
combined), we could not ascertain the individual contribution of each
ADHD component, which should be explored in future studies.
Perhaps the most relevant and striking result was the protective
effect of ADHD medication (mainly methylphenidate per prescription
rates in the included studies). This relied on the combination of studies
with a very powerful type of design, i.e., self-controlled case studies and
difference in risk differences, which control for the “confounding by
indication bias”. It must be noted that the effect size included for the
latter study was an OR that did not directly control for intra-individual
characteristics. However, the fact that the protection estimated through
the difference in difference model was greater than that obtained from
the linear mixed model from which the OR was derived indicates that
the pooled estimation when including all the articles, is, if anything, a
conservative one.
Although one may think that our finding should be taken with
caution since it derives from 5 studies only, we note that this analysis
included 13,254 children/adolescents with ADHD. Additionally, while
the results of the risk meta-analysis were characterized by a high het-
erogeneity (likely accounted for by the variability that we addressed
with the sensitivity and meta-regression analyses), the meta-analysis on
the effect of medication was associated with a low heterogeneity, in-
creasing the confidence in the results. The effect size we found in re-
lation to the protective effect of ADHD medications translates in an
average of 10% reduction in the incidence of unintentional injuries.
Whilst this figure may seem small, we deem our results relevant from a
clinical and public health standpoint. Indeed due to the high prevalence
of ADHD in children and adolescents, and the higher incidence of un-
intentional injuries in this population, even a small reduction of the risk
would result in high potential social and economic benefits. Our results
on the effect of the medication complement findings from a large body
of evidence showing beneficial effects of ADHD medications not only in
the short term, for ADHD core symptoms (Faraone and Buitelaar,
2010), but also for neuropsychological dysfunctions (Coghill et al.,
2014) and for other very relevant outcomes, such as criminal acts both
in adolescents (Dalsgaard et al., 2014) and adults with ADHD
(Lichtenstein et al., 2012). Our findings are also important in the light
of recent controversy about the evidence supporting the use of me-
thylphenidate (Banaschewski et al., 2016).
Self-controlled case series are suited to estimate the short-term ef-
fects of medication as the issue they address is whether an individual is
more prone to suffer an injury during the previous, recent, period when
(s)he has not taken any ADHD drugs. Our meta-analysis of the four self-
controlled case series shows that there is a short-term protective effect
of medication. However, the study by Dalsgaard et al. (Dalsgaard et al.,
2015a) investigated long-term differences in the risk of injuries, as in-
dividuals were included in the medicated group if they had received
medication for as little time as six months. As already reported, this
study showed a similar effect size to the self-controlled studies, and its
inclusion in the meta-analysis did not change the estimation of the
pooled effect-size. Future additional studies are needed to confirm the
possible long-term protective effect of medication reported by Dals-
gaard et al.
Overall, our results have relevant implications both from a research
and clinical perspective. In terms of research, there has been for a long
time a strong focus on the cognitive and academic impairments asso-
ciated with ADHD. Indeed, many parents seek help only when there are
academic failures or learning difficulties. More recently, there has been
a growing interest on other very relevant aspects related to ADHD, such
as somatic disorders (e.g, obesity (Cortese et al., 2016)) substance abuse
(Groenman et al., 2017), sexual impulsivity −associated with higher
rates of sexually transmitted diseases and un-planned pregnancy-
(Ramos Olazagasti et al., 2013), legal problems and motor vehicle ac-
cidents (Barkley et al., 1990; Curry et al., 2017) and quality of life
(Coghill et al., 2017). Our results add to this body of literature high-
lighting how UPIs are a significant aspect to consider.
The association of ADHD with higher risk of UPIs has also important
clinical and preventive medicine implications. Children and adolescents
with ADHD are an “at risk” population for injuries, and prevention is
the best way to tackle this problem (Peden et al., 2008). Parents of
children and adolescents with ADHD should have a stronger focus on
child-proofing the home to avoid injuries and also educate their chil-
dren in the use of protective equipment in sports, and more generally,
to avoid unneeded risks.
From an economic perspective, arguably, medication management
is not a low-cost intervention, as a continuous clinical follow up and a
close monitoring of parameters such as weight, height, blood pressure,
and pulse are recommended. However, the potential reduction of UPIs
would save a lot of resources in direct costs, such as visits to the
emergency room, hospital admissions, severe disability (physical or
cognitive) or premature death; and also in indirect costs such as school
absenteeism, parental stress and parental reduction of time at work
(Maia et al., 2016).
Clinically, our finding on the reduction of risk of UPIs with medi-
cation highlights the importance of balancing risk and benefits when
deciding to start, stop or continue medication. This should be con-
sidered during a balanced discussion over the pros and cons of medi-
cation therapy with parents so they can make an informed choice over
therapeutic options that takes into account short and long-term out-
comes. Moreover, medication discontinuation during the summer is a
practice that is still frequent in many settings (Ibrahim and Donyai,
2015), as ADHD is sometimes identified only as a school performance
problem. However, the risk of UPIs is especially high in this period of
the year (Peden et al., 2008), and hence, our results are a further call for
the reconsideration of this practice. At the very least, when the clin-
icians discuss the potential benefits on appetite, sleep, mood and other
aspects when the medication is stopped, they should also address the
risk of elevated injuries, in times when there is less structure and su-
pervisions, such as summer vacation.
Our results should be evaluated in the light of study strengths and
limitations. The former include the availability of a pre-registered
protocol, limiting the possibility of reporting bias, the inclusion of un-
published data, and the focus, for the medication analysis, on studies
with a very rigorous design suited to test medication effects, i.e., self-
case control studies. As for all meta-analyses, limitations include: 1)
bias on individual studies (although our meta-regression showed that
study quality did not have a significant impact on the findings); 2)
number of studies available for meta-regression analyses; 3) the im-
possibility of studying whether the protective effect varies between
medications, if it is influenced by other variables, or if non-pharma-
cological interventions can also influence this risk. These limitations
should be addressed with future studies and meta-analyses.
5. Conclusion
Our study provides meta-analytic evidence showing that children
and adolescents with ADHD are at higher risk of injuries and that ADHD
pharmacotherapy has a protective effect, at least in the short-term.
These findings are highly relevant from a clinical and public health
perspective.
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